Earlier studies showed that IA-2 and IA-2beta are enzymatically inactive members of the protein tyrosine phosphatase family, widely distributed in neuroendocrine cells throughout the body and transmembrane components of DCV. Further studies showed that IA-2/IA-2beta belong to an ancient gene family going back 500 million years with homologs in Drosophila and C. elegans Studies over the last year, in mice, showed that IA-2/IA-2beta which influences the secretion of hormones also modulates the secretion of neurotransmitters in the brain. These observations led to the discovery that the knockout of the IA-2/IA-2beta genes resulted in profound changes in behavior, learning and lifespan. Additional studies revealed that the knockout of IA-2/IA-2beta also had a profound effect on the circadian rhythm of blood pressure;heart rate, body temperature and physical activity. These observations point to the possibility that in mice and in humans, alterations in one or more of the many non-circadian structural proteins of secretory vesicles may similarly affect circadian timing and, in turn, a variety of other physiological functions. Little is known about the genes that regulate DCV biogenesis and cargo packaging. To study this problem we made a transgenic worm (C. elegans) expressing IA-2::GFP which was expressed in many neurons. We then mutagenized these worms with methanesulfonate. About one-half million worms were visually screened with a dissecting fluorescence microscope for high and low expression of IA-2::GFP in the neurons of mutagenized as compared to non-mutagenized worms. One of these worms (designated gv560) showed high expression of IA-2::GFP in many neurons and further studies revealed that the mutation occurred in the zinc finger transcriptional repressor pag-3. Electron microscopy revealed a marked increase in the number of DCV. To our knowledge, this is the first mutation identified that results in increased biogenesis of DCV. Screening of mutagenized worms expressing IA-2::GFP should lead to the discovery of other genes that regulate DCV biogenesis and cargo packaging.

Project Start
Project End
Budget Start
Budget End
Support Year
24
Fiscal Year
2009
Total Cost
$1,511,434
Indirect Cost
Name
National Institute of Dental & Craniofacial Research
Department
Type
DUNS #
City
State
Country
Zip Code
Gunti, Sreenivasulu; Herman, Sarah E M; Gottumukkala, Raju V S R K et al. (2018) Polyreactive antibodies in CLL correlate with the level of immunoglobulins not the number of B lymphocytes. Leuk Lymphoma :1-4
Burbelo, Peter D; Gunti, Sreenivasulu; Keller, Jason M et al. (2017) Ultrarapid Measurement of Diagnostic Antibodies by Magnetic Capture of Immune Complexes. Sci Rep 7:3818
Cai, Tao; Notkins, Abner L (2016) Pathophysiologic changes in IA-2/IA-2? null mice are secondary to alterations in the secretion of hormones and neurotransmitters. Acta Diabetol 53:7-12
Gunti, Sreenivasulu; Notkins, Abner Louis (2015) Polyreactive Antibodies: Function and Quantification. J Infect Dis 212 Suppl 1:S42-6
Pfeifer, C R; Shomorony, A; Aronova, M A et al. (2015) Quantitative analysis of mouse pancreatic islet architecture by serial block-face SEM. J Struct Biol 189:44-52
Gunti, S; Kampylafka, E I; Tzioufas, A G et al. (2015) Polyreactive antibodies in the circulation of patients with systemic lupus erythematosus. Lupus 24:1567-9
Abuhatzira, Liron; Xu, Huanyu; Tahhan, Georges et al. (2015) Multiple microRNAs within the 14q32 cluster target the mRNAs of major type 1 diabetes autoantigens IA-2, IA-2?, and GAD65. FASEB J :
Qiu, Qi; Xu, Zhili; Tian, Jie et al. (2015) Impact of natural IgM concentration on gene therapy with adenovirus type 5 vectors. J Virol 89:3412-6
Xu, Huanyu; Abuhatzira, Liron; Carmona, Gilberto N et al. (2015) The Ia-2? intronic miRNA, miR-153, is a negative regulator of insulin and dopamine secretion through its effect on the Cacna1c gene in mice. Diabetologia 58:2298-306
Sun, Clare; Tian, Xin; Lee, Yuh Shan et al. (2015) Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood :

Showing the most recent 10 out of 30 publications